research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
Search
for
Sort by
Research
540-570 / 1000+ results research Position of systemic therapy in the treatment of lichen pigmentosus
Tranexamic acid and oral retinoids may effectively treat lichen plan pigmentosus.
research Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real‐Life Experience in the Lazio Region
Baricitinib may help people with long-term alopecia areata.
research Drug repositioning approach to target viral and host cells in terms of COVID-19 treatment: A review of in vivo experiments and clinical studies
Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
research Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
Rituximab can cause skin issues, but baricitinib may help improve them.
research TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
research CYP3A5 Polymorphism in Circulating Tumor Cells Confers an Increased Disease-Free Survival in DLBCL Patients Treated with R-CHOP
A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.
research High‐dose mizoribine treatment for adolescents with systemic lupus erythematosus
High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.
research Anais do II Congresso Nacional Acadêmico de Dermatologia
Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.
research Adalimumab-induced psoriatic alopecia/alopecia areata-like reaction in a patient with Crohn's disease
A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Diffuse plate-like sheets of desquamation
The rash resolved after stopping ponatinib.
research 270 A novel small compound HPH-15 antagonizes TGF-β/Smad signaling and ameliorates experimental skin fibrosis
HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.
research Editorial: Exploring innovative therapies for rare inflammatory skin diseases
New therapies for rare skin diseases show promise but need more research.
research Reversible Alopecia Universalis During Treatment with PEG-Interferon and Ribavirin for Chronic Hepatitis C
Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
research Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients
Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
research JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Patient-Reported Flare Symptoms Following COVID-19 Vaccination in Systemic Lupus Erythematosus
COVID-19 vaccines are generally safe for people with lupus, though some may experience mild flare symptoms.
research Safety of dermatologic medications in pregnancy and lactation
Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
research Застосування кріоконсервованої плаценти в комплексному лікуванні флегмон щелепно-лицевої локалізації
research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Modified phenol peels for treatment‐refractory hyperpigmentation of lichen planus pigmentosus: A retrospective clinico‐dermoscopic analysis
Modified phenol peels effectively reduced stubborn skin pigmentation in patients with Lichen Planus Pigmentosus.
research EXPERIENCE WITH ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH NEUROLOGICAL MANIFESTATIONS
Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.
research Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.